Mr Michael Spiegel


Mr Michael Spiegel is the General Manager – Corporate Services. He is also the Acting CEO of Neuroscience Trial Australia (NTA). Mr Spiegel is an accomplished entrepreneurial leader with an executive career and NED experience spanning more than two decades and eight countries within start-ups, corporates, government, academia and not-for-profit sectors.

His unique experience ranges from establishing a world-first automated antibody facility in Australia, a mobile app start-up, a German DNA engineering biotech company and multiple management positions in tech start-ups, finance and banking. He has a successful track record creating, productising, scaling and commercialising complex projects and innovative life sciences platforms to address changing market and community needs.

Prior to arriving in Australia in 2007, Mr Spiegel spent 15 years in Europe, working at the European Molecular Biology Laboratory (EMBL) in Germany and Italy, as well as a founding executive of Gene Bridges GmbH, a biotechnology company focused on genetic engineering using novel DNA technology where he successfully led technology licensing deals with major international pharma and biotech companies.

With over 20+ years international experience in the sector, he was on the Tecan AG Scientific Advisory Panel on Biotherapeutics from 2008–2010, a Committee Member for the Victorian Biotechnology Action Plan 2011, and Executive Secretary of the Leadership Advisory Board for the $153 million Australian Regenerative Medicine Institute (ARMI).

His expertise includes strategy, growth, leadership, cultural realignments and transformations, and stakeholder relations.

Mr Spiegel is a sought-after speaker and commentator on topics relating to biotech, complexity, innovation, start-ups and scale-ups, leadership, culture and courage.

Mr Spiegel holds an MSc, MBA and is a graduate of the Australian Institute of Company Directors (GAICD).

Michael Spiegel